Successful treatment of chromoblastomycosis caused by Fonsecaea pedrosoi using imiquimod
Carregando...
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2020
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
Citação
JOURNAL OF DERMATOLOGY, v.47, n.4, p.409-412, 2020
Resumo
Chromoblastomycosis (CBM) is a fungal infection caused by fungi belonging to the order Chaetothyriales, and caused mainly by Fonsecaea pedrosoi. The classic treatment, based on itraconazole and/or terbinafine as well as physical approaches, is considered complex and ineffective due to the high rate of relapses. Thus, new strategies are needed to manage CBM; in this regard, the present work reports the evolution of lesions in patients successfully treated with imiquimod. Of note, classic treatment was not effective in healing the lesions of two of them, but single topical treatment with imiquimod healed the lesions.
Palavras-chave
chromoblastomycosis, Fonsecaea pedrosoi, imiquimod, lesion evolution, treatment
Referências
- Ameen M, 2009, CLIN EXP DERMATOL, V34, P849, DOI 10.1111/j.1365-2230.2009.03415.x
- BARBAGOMEZ JF, 1992, J AM ACAD DERMATOL, V26, P367, DOI 10.1016/0190-9622(92)70058-N
- Buates S, 1999, J INFECT DIS, V179, P1485, DOI 10.1086/314782
- Cao Z, 2018, MOL MED REP, V17, P7122, DOI 10.3892/mmr.2018.8734
- de Hoog GS, 2004, MED MYCOL, V42, P405, DOI 10.1080/13693780410001661464
- El Hajj R, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006854
- Erbagci Z, 2005, MYCOPATHOLOGIA, V159, P521, DOI 10.1007/s11046-005-5260-z
- Najafzadeh MJ, 2010, MED MYCOL, V48, P800, DOI 10.3109/13693780903503081
- NAKA W, 1986, MYCOSES, V29, P445
- Queiroz-Telles F, 2009, MED MYCOL, V47, P3, DOI 10.1080/13693780802538001
- Siqueira SM, 2019, AN BRAS DERMATOL, V94, P221, DOI 10.1590/abd1806-4841.20198014
- Stashower ME, 2006, CUTIS, V78, P66
- Stein P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102664
- de Sousa MDT, 2014, CLIN INFECT DIS, V58, P1734, DOI 10.1093/cid/ciu168
- Telo I, 2016, INT J PHARMACEUT, V511, P516, DOI 10.1016/j.ijpharm.2016.07.043